Theravac (docusate)

Thus, MSN@TheraVac provides a timely release of TheraVac for the curative treatment of colon tumors and holds potential for translation into a clinical therapy for patients with immunologically "cold" colorectal cancers. This ROS-responsive MSN platform may also be tailored for the selective delivery of other cancer vaccines for effective immunotherapy.

The resultant tumor-free mice were resistant to subsequent re-challenge with the same tumors, indicating the generation of long-term tumor specific protective immunity. Since the immune-activating arm also induces full maturation of human DCs, and anti-PDL-1 or anti-CTLA4 have been FDA-approved, this combinational immunotherapy has the potential to be an effective clinical therapy for patients with solid tumors.

We have identified a combinational immunotherapy termed TheraVac vaccine (TheraVac) that can cure multiple large established mouse tumors, but it failed to cure melanoma in mice...The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor-specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of these immunotherapeutics to cure melanin-producing human melanomas, without the need for exogenous tumor Ags and no clear toxic effects in mice.

The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of immunotherapeutics to cure melanin producing human melanomas, without the need for exogenous tumor antigens and no obvious toxic effects in mice.

The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of immunotherapeutics to cure melanin producing human melanomas, without the need for exogenous tumor antigens and no obvious toxic effects in mice.

The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of immunotherapeutics to cure melanin producing human melanomas, without the need for exogenous tumor antigens and no obvious toxic effects in mice.

The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of immunotherapeutics to cure melanin producing human melanomas, without the need for exogenous tumor antigens and no obvious toxic effects in mice.